Our lab develops new ways to engineer the immune system to more effectively treat pediatric cancers. Despite major advances, cancer remains a leading cause of death in children, and current therapies like chemotherapy and radiation often cause lasting side effects. Immunotherapy offers a more precise approach by training the immune system to target cancer cells while sparing healthy tissue. We focus on chimeric antigen receptor (CAR) technologies, which reprogram a patient’s own cells to recognize and eliminate tumors. Because traditional CAR discovery is slow and one-by-one, we have created high-throughput methods to test thousands of CAR designs simultaneously. These innovations aim to accelerate the development of safer, more effective therapies.